Research programme: gastric cancer-targeted radioimmunoconjugates - Actinium
Alternative Names: D9-e-Cadherin-Ac-225; delta9MAB; δ9MABLatest Information Update: 16 Jul 2016
At a glance
- Originator GSF-National Research Center for Environment and Health
- Developer Actinium Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastric-cancer in USA (IV, Infusion)